Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
Clementia will present a poster detailing updated data from its Phase 2 clinical trial of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP) at the ASBMR 2018 Annual Meeting.
Details are as follows:
Abstract Title: Palovarotene Reduces New Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva (FOP) (Presentation Number: MON-1066)
Date and Time:
Location: ASBMR Discovery Hall – Exhibit Hall 220 B-E
- The Morgan Stanley Annual Global Healthcare Conference in
New York Cityon Wednesday, Sept. 12, 2018at 3:40 p.m. ET The Leerink Partners2018 Rare Disease Roundtable in New York Cityon Tuesday, Oct. 2, 2018at 2:00 p.m. ET
Webcasts of the
Clementia is a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead product candidate, palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP) and in the Phase 2 MO-Ped Trial to treat multiple osteochondromas (MO, also known as multiple hereditary exostoses/MHE). Clementia is also investigating palovarotene for the potential treatment of other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
THRUST Strategic Communications
Source: Clementia Pharmaceuticals Inc.